Abstract
Bladder cancer treatment, namely systemic therapy, was dominated in the last three decades due to the absence of newer therapeutic options other than chemotherapy regimens. Chemotherapy, by itself, both in first and second-line seems to have achieved the modest plateau of its possibilities at the cost of non-negligible toxicity. Targeted therapies, which changed the therapy of many different tumors, seem rather ineffective in bladder cancer. More recently, a new generation of Immunotherapy based regimens represent the most promising avenue for the future systemic treatment of bladder cancer. Checkpoint inhibition, namely PD1/PD-L1 pathway inhibition, showed impressive results in many other tumor types and are expected to become a major player in the treatment of bladder cancer. Other immunotherapy strategies such as fusion proteins represent distant, although promising, options. A brief overview of the current status of bladder cancer immunotherapy is presented.
Keywords: Bladder cancer, clinical trials, immunotherapy, urothelial carcinoma.
Current Drug Targets
Title:Emerging Immunotargets in Bladder Cancer
Volume: 17 Issue: 7
Author(s): Francesco Massari, Chiara Ciccarese, Nuno Vau, Matteo Santoni, Rodolfo Montironi, Liang Cheng, Rita C. Marques, Marina Scarpelli, Jorge Fonseca, Marc R Matrana, Moch Holger, Stefano Cascinu, Giampaolo Tortora and Antonio Lopez-Beltran
Affiliation:
Keywords: Bladder cancer, clinical trials, immunotherapy, urothelial carcinoma.
Abstract: Bladder cancer treatment, namely systemic therapy, was dominated in the last three decades due to the absence of newer therapeutic options other than chemotherapy regimens. Chemotherapy, by itself, both in first and second-line seems to have achieved the modest plateau of its possibilities at the cost of non-negligible toxicity. Targeted therapies, which changed the therapy of many different tumors, seem rather ineffective in bladder cancer. More recently, a new generation of Immunotherapy based regimens represent the most promising avenue for the future systemic treatment of bladder cancer. Checkpoint inhibition, namely PD1/PD-L1 pathway inhibition, showed impressive results in many other tumor types and are expected to become a major player in the treatment of bladder cancer. Other immunotherapy strategies such as fusion proteins represent distant, although promising, options. A brief overview of the current status of bladder cancer immunotherapy is presented.
Export Options
About this article
Cite this article as:
Massari Francesco, Ciccarese Chiara, Vau Nuno, Santoni Matteo, Montironi Rodolfo, Cheng Liang, C. Marques Rita, Scarpelli Marina, Fonseca Jorge, R Matrana Marc, Holger Moch, Cascinu Stefano, Tortora Giampaolo and Lopez-Beltran Antonio, Emerging Immunotargets in Bladder Cancer, Current Drug Targets 2016; 17 (7) . https://dx.doi.org/10.2174/1389450117666160201105537
DOI https://dx.doi.org/10.2174/1389450117666160201105537 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Human Leukemia and Lymphoma Cell Lines as Models and Resources
Current Medicinal Chemistry Cathelicidins: Peptides with Antimicrobial, Immunomodulatory, Anti- Inflammatory, Angiogenic, Anticancer and Procancer Activities
Current Protein & Peptide Science Autoimmune Neuromuscular Disorders
Current Neuropharmacology Diabetes and Its Complications: Therapies Available, Anticipated and Aspired
Current Diabetes Reviews The Coordinated Role of CYP450 Enzymes and P-gp in Determining Cancer Resistance to Chemotherapy
Current Drug Metabolism Combined Chemotherapy or Biotherapy with Jasmonates: Targeting Energy Metabolism for Cancer Treatment
Current Pharmaceutical Biotechnology Polymorphisms of Human N-Acetyltransferases and Cancer Risk
Current Drug Metabolism Physical and Chemical Stimuli-Responsive Drug Delivery Systems: Targeted Delivery and Main Routes of Administration
Current Pharmaceutical Design Secreted Heat Shock Protein-90α: A More Effective and Safer Target for Anti-Cancer Drugs?
Current Signal Transduction Therapy Diagnostic, Prognostic and Therapeutic Potential of Heat Shock Proteins in Schistosomiasis and Bladder Cancer: A Review
Letters in Drug Design & Discovery Radioiodinated Agents for Imaging Multidrug Resistant Tumors
Medicinal Chemistry Engineered Nanoparticles for Improved Vasoactive Intestinal Peptide (VIP) Biomedical Applications
Recent Patents on Nanomedicine Inhibition of Proliferation of ECV304 Cells by a Disintegrin from Chinese Green Tree Viper
Protein & Peptide Letters Flavonoid-Based Cancer Therapy: An Updated Review
Anti-Cancer Agents in Medicinal Chemistry Recurrence in Bladder Cancer: A Molecular Dead End?
Current Genomics Cardiac Side Effects of Chemotherapy: State of Art and Strategies for a Correct Management
Current Vascular Pharmacology Non-viral Delivery Systems for the Application in p53 Cancer Gene Therapy
Current Medicinal Chemistry The Accomplices of NF-κB Lead to Radioresistance
Current Protein & Peptide Science The Synergistic Effect of Humanized Monoclonal Antibodies Targeting Insulin-Like Growth Factor 1 Receptor (IGF-1R) and Chemotherapy
Current Drug Targets microRNA-133: Expression, Function and Therapeutic Potential in Muscle Diseases and Cancer
Current Drug Targets